Home Equities Score Reasons why investors should trust Edesa Biotech Inc. (EDSA) for the long-term

Reasons why investors should trust Edesa Biotech Inc. (EDSA) for the long-term

Edesa Biotech, Inc. (NASDAQ: EDSA) shares were trending lower in the pre-market as it seems to give back some of its gains from last night’s close. A total of +46.95% has been achieved by the EDSA stock over the past five days, from $5.01 to $9.10. In the past month of trading, this stock has moved from $4.05 to $9.10, a change of +56.16%. For the past three months, this stock’s price changed by +18.17%, trading in the range of $4.05 to $9.10.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.  

What they do…

5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored

Edesa Biotech, Inc. is focused on developing innovative treatments for inflammatory and immune-related illnesses with significant unmet medical needs. Both EB05 and EB01, the company’s leading product candidates, are in late-stage clinical trials.

Read More

What happened…

The company has received FDA / Health Canada approval to add to the ongoing Phase 2/ Phase 3 clinical study of Edesa Biotech (NASDAQ: EDSA) to treat Acute Respiratory Distress Syndrome (ARDS), the leading cause of death in COVID-19 patients. In this substudy, the drug will be examined as potential COVID-19 rescue therapy.

Chief Executive Officer of Edesa, Dr. Par Nijhawan, told physicians involved in the company’s ARDS study that the company identified a group of COVID-19 patients who could benefit from the experimental treatment but weren’t well enough for the main study. Dr. Nijhawan said this sub-study expands the ability to treat critically ill patients suffering from profound, medically refractory COVID 19 respiratory failure.

One sub-study of Edesa is expected to enroll up to 100 in-hospital patients with severe COVID-19 symptoms, including patients receiving extracorporeal membrane oxygenation (ECMO) therapy or being ventilated for more than five days. The sub-study is not expected to affect the design or results of Edesa’s ongoing international Phase 2/3 study.

The Vice President of Research and Development at Edesa, Blair Gordon, PhD., stated that all data would be aggregated and metered together. There will be separate analyses of the sub-study and the main study, which are identical except for the patient enrollment criteria. The study design’s efficiency enables us to efficiently assess the utility of the EB05 across a broad range of hospitalized patients.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.  

Summary

FactSet Research has revealed that one brokerage house has rated the stock as a buy. No analysts have rated it as a sell or overweight. One analyst has given it a buy recommendation. Meanwhile, the consensus is a buy rating.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Why AbCellera Biologics Inc. (ABCL) stock faced negativity on Tuesday?

AbCellera Biologics Inc. (ABCL) shares lost 2.13% in after-hours on Tuesday, June 22, 2021, and closed the day at $21.60 per share. Earlier, ABCL's...

Biocept Inc. (BIOC) stock surged during current market trading. Why is it so?

Biocept Inc. (NASDAQ: BIOC) stock gained by 3.13% in the current market trading. Biocept creates and sells molecular diagnostic tests that offer doctors with...

Comstock Mining Inc. (LODE) stock soar during pre-market trading. What’s happening?

Comstock Mining Inc. (NASDAQ: LODE) stock gained by 1.14% at last close while the LODE stock price surged by 3.10% in the pre-market trading...

Why MediciNova Inc (MNOV) stock facing negativity since Monday’s after-hours?

MediciNova Inc. (MNOV) shares lost 5.71% in after-hours on Monday, June 21, 2021, and the plummeting continues in the pre-market session on Tuesday as...

Here is why Sanderson Farms Inc. (SAFM) stock rallied on Monday?

Sanderson Farms Inc. (SAFM) shares surged 10.16% in after-hours on Monday, June 21, 2021, and close the day at $183.50 per share. Earlier in...

Pyxis Tankers Inc. (PXS) stock fell during pre-market trading. Why so?

Pyxis Tankers Inc. (NASDAQ: PXS) stock declined by 0.06% at the last close while the PXS stock price plunged by 6.15% in the pre-market...

Why STAAR Surgical Company (STAA) stock went up on Tuesday?

STAAR Surgical Company (STAA) shares rose 5.84% in after-hours on Tuesday, June 22, 2021, and closed the day at $151.25 per share. earlier in...

Why AbCellera Biologics Inc. (ABCL) stock faced negativity on Tuesday?

AbCellera Biologics Inc. (ABCL) shares lost 2.13% in after-hours on Tuesday, June 22, 2021, and closed the day at $21.60 per share. Earlier, ABCL's...

Related News

Pyxis Tankers Inc. (PXS) stock fell during pre-market trading. Why so?

Pyxis Tankers Inc. (NASDAQ: PXS) stock declined by 0.06% at the last close while the PXS stock price plunged by 6.15% in the pre-market...

Globalstar Inc. (NASDAQ: GSAT) stock surged during after-hour session. Here’s the update:

Globalstar Inc. (NASDAQ: GSAT) stock gained by 23.18% at last close while the GSAT stock price rises by 4.3% in the after-hours session. Globalstar...

Millendo Therapeutics Inc. (MLND) stock plunged during after-hour session. Here’s to know why?

Millendo Therapeutics Inc. (NASDAQ: MLND) stock gained by 3.76% at the last close while the MLND stock price declines by 13.04% in the after-hours...

Bio-Path Holdings Inc. (BPTH) stock gains during current market trading. Here’s to know why?

Bio-Path Holdings Inc. (NASDAQ: BPTH) stock surged by 8.76% in the current market trading. Bio-Path is a biotech firm working on DNAbilize, a new...

Vinco Ventures, Inc. (BBIG) stock surged during pre-market trading, given no recent news.

Vinco Ventures, Inc. (NASDAQ: BBIG) stock gained by 11.75% at last close whereas the BBIG surged by 7.38% in the pre-market trading. Vinco Ventures...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam